Comparative Pharmacology
Head-to-head clinical analysis: CICLOPIROX versus NYSERT.
Head-to-head clinical analysis: CICLOPIROX versus NYSERT.
CICLOPIROX vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Clinical Note
moderateCiclopirox + Tranilast
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast."
Clinical Note
moderateCiclopirox + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tolfenamic acid."
Clinical Note
moderateCiclopirox + Nimesulide
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide."
Clinical Note
moderateCiclopirox + Risedronic acid
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category A/B
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronic acid."